vs
Side-by-side financial comparison of Moderna (MRNA) and Snap-on (SNA). Click either name above to swap in a different company.
Snap-on is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.2× Moderna). Snap-on runs the higher net margin — 21.3% vs -19.7%, a 41.0% gap on every dollar of revenue. On growth, Snap-on posted the faster year-over-year revenue change (2.7% vs -45.4%). Snap-on produced more free cash flow last quarter ($254.6M vs $-880.0M). Over the past eight quarters, Snap-on's revenue compounded faster (2.0% CAGR vs -45.0%).
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Snap-on Incorporated is an American designer, manufacturer, and marketer of high-end tools and equipment for professional use in the transportation industry, including the automotive, heavy duty, equipment, marine, aviation, and railroad industries. Headquartered in Kenosha, Wisconsin, since 1930, Snap-on also distributes lower-end tools under the brand name Blue-Point. Their primary competitors include Matco, Mac Tools, and Cornwell Tools.
MRNA vs SNA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.2B |
| Net Profit | $-200.0M | $260.7M |
| Gross Margin | 79.6% | — |
| Operating Margin | -25.6% | 27.8% |
| Net Margin | -19.7% | 21.3% |
| Revenue YoY | -45.4% | 2.7% |
| Net Profit YoY | -1638.5% | 1.0% |
| EPS (diluted) | $-0.51 | $4.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $966.0M | $1.2B | ||
| Q3 24 | $1.9B | $1.1B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $260.7M | ||
| Q3 25 | $-200.0M | $265.4M | ||
| Q2 25 | — | $250.3M | ||
| Q1 25 | — | $240.5M | ||
| Q4 24 | $-1.1B | $258.1M | ||
| Q3 24 | $13.0M | $251.1M | ||
| Q2 24 | — | $271.2M | ||
| Q1 24 | — | $263.5M |
| Q4 25 | — | — | ||
| Q3 25 | 79.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 72.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 27.8% | ||
| Q3 25 | -25.6% | 29.4% | ||
| Q2 25 | — | 28.0% | ||
| Q1 25 | — | 27.7% | ||
| Q4 24 | -129.0% | 27.9% | ||
| Q3 24 | -3.8% | 28.4% | ||
| Q2 24 | — | 29.9% | ||
| Q1 24 | — | 28.9% |
| Q4 25 | — | 21.3% | ||
| Q3 25 | -19.7% | 22.5% | ||
| Q2 25 | — | 21.4% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | -115.9% | 21.7% | ||
| Q3 24 | 0.7% | 22.0% | ||
| Q2 24 | — | 23.1% | ||
| Q1 24 | — | 22.4% |
| Q4 25 | — | $4.94 | ||
| Q3 25 | $-0.51 | $5.02 | ||
| Q2 25 | — | $4.72 | ||
| Q1 25 | — | $4.51 | ||
| Q4 24 | $-2.91 | $4.83 | ||
| Q3 24 | $0.03 | $4.70 | ||
| Q2 24 | — | $5.07 | ||
| Q1 24 | — | $4.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.3B | — |
| Total Assets | $12.1B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $1.9B | $1.4B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $9.3B | $5.8B | ||
| Q2 25 | — | $5.7B | ||
| Q1 25 | — | $5.5B | ||
| Q4 24 | $10.9B | $5.4B | ||
| Q3 24 | $11.9B | $5.5B | ||
| Q2 24 | — | $5.3B | ||
| Q1 24 | — | $5.1B |
| Q4 25 | — | — | ||
| Q3 25 | $12.1B | $8.4B | ||
| Q2 25 | — | $8.2B | ||
| Q1 25 | — | $8.1B | ||
| Q4 24 | $14.1B | $7.9B | ||
| Q3 24 | $15.8B | $8.0B | ||
| Q2 24 | — | $7.8B | ||
| Q1 24 | — | $7.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-847.0M | $268.1M |
| Free Cash FlowOCF − Capex | $-880.0M | $254.6M |
| FCF MarginFCF / Revenue | -86.6% | 20.8% |
| Capex IntensityCapex / Revenue | 3.2% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 1.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9B | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-847.0M | $277.9M | ||
| Q2 25 | — | $237.2M | ||
| Q1 25 | — | $298.5M | ||
| Q4 24 | $825.0M | $293.5M | ||
| Q3 24 | $-1.6B | $274.2M | ||
| Q2 24 | — | $301.1M | ||
| Q1 24 | — | $348.7M |
| Q4 25 | — | $254.6M | ||
| Q3 25 | $-880.0M | $258.0M | ||
| Q2 25 | — | $217.5M | ||
| Q1 25 | — | $275.6M | ||
| Q4 24 | $303.0M | $275.4M | ||
| Q3 24 | $-1.7B | $253.8M | ||
| Q2 24 | — | $277.9M | ||
| Q1 24 | — | $326.9M |
| Q4 25 | — | 20.8% | ||
| Q3 25 | -86.6% | 21.8% | ||
| Q2 25 | — | 18.6% | ||
| Q1 25 | — | 24.3% | ||
| Q4 24 | 31.4% | 23.1% | ||
| Q3 24 | -92.2% | 22.3% | ||
| Q2 24 | — | 23.7% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | 3.2% | 1.7% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | 54.0% | 1.5% | ||
| Q3 24 | 8.1% | 1.8% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.9% |
| Q4 25 | — | 1.03× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | -120.46× | 1.09× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
SNA
Segment breakdown not available.
